249 related articles for article (PubMed ID: 31610537)
21. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
[TBL] [Abstract][Full Text] [Related]
22. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
[TBL] [Abstract][Full Text] [Related]
24. Coordinating emergent procedures after andexanet alfa.
Culbreth SE; Sylvester KW; Rimsans J; Connors JM
Am J Hematol; 2019 Oct; 94(10):E278-E282. PubMed ID: 31342554
[No Abstract] [Full Text] [Related]
25. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
Rech MA; Masic D; Hammond DA
West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
[TBL] [Abstract][Full Text] [Related]
26. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM;
Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209
[TBL] [Abstract][Full Text] [Related]
27. Intraosseous administration of 4-factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban.
Ratliff P; Nutley K; Schroeder W; Cottingham L
J Clin Pharm Ther; 2020 Jun; 45(3):577-579. PubMed ID: 31805210
[TBL] [Abstract][Full Text] [Related]
28. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
[TBL] [Abstract][Full Text] [Related]
30. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
31. Andexanet alfa-The first 150 days.
Culbreth SE; Rimsans J; Sylvester K; Pallin DJ; Connors JM
Am J Hematol; 2019 Jan; 94(1):E21-E24. PubMed ID: 30358896
[No Abstract] [Full Text] [Related]
32. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
[No Abstract] [Full Text] [Related]
33. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Meddahi S; Samama MM
J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
[TBL] [Abstract][Full Text] [Related]
35. Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series.
Schultz NH; Lundblad R; Holme PA
J Med Case Rep; 2018 May; 12(1):138. PubMed ID: 29764497
[TBL] [Abstract][Full Text] [Related]
36. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
37. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic interventions for reversing the effects of oral anticoagulants.
Kalus JS
Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
[TBL] [Abstract][Full Text] [Related]
39. Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis.
Ito H
Eur J Intern Med; 2024 Jun; 124():154-155. PubMed ID: 38342714
[No Abstract] [Full Text] [Related]
40. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
